奈米孔定序市场 - 全球产业规模、份额、趋势、机会及预测（按产品类型、序列类型、奈米孔类型、应用、最终用户、地区和竞争格局划分），2021-2031年

全球奈米孔定序市场预计将从2025年的4.3174亿美元成长到2031年的7.9066亿美元，复合年增长率（CAGR）为10.61%。该技术透过监测核酸穿过固体或蛋白质中的奈米孔时产生的电流波动来确定核苷酸序列。市场成长的主要驱动力是：对用于解析复杂结构变异的长读长定定序的需求不断增长，以及对分散式环境中携带式病原体监测的需求日益增长。世界卫生组织（WHO）在2024年报告称，国际病原体监测网络已向计划提供了约200万美元的津贴凸显了此类诊断基础设施的重要性。

儘管有这些驱动因素，但市场普及的一大障碍在于，校正原始资料读取错误率所需的资料分析十分复杂，而原始资料读取错误率仍然高于传统的短读长定序系统。这项技术限制需要强大的运算能力才能进行准确解读，这为缺乏先进生物资讯基础设施的小规模实验室设置了很高的进入门槛。因此，数据处理资源密集的特性继续阻碍这项技术在技术资源有限的机构中的广泛应用。

市场驱动因素

临床诊断和精准医疗领域应用的不断拓展，正成为全球奈米定序市场的主要成长动力。随着技术的进步，奈米孔定序正从研究环境走向受监管的医疗机构，用于快速病原体鑑定和人类基因分析。医院对奈米孔测序检测方法的日益普及，充分体现了这一转变，因为与传统方法相比，奈米孔测序能够提供更快的检测结果。根据FirstWord HealthTech发布的牛津奈米孔公司2025年9月中期财务报告，其临床收入年增52.9%，显示这些诊断工具在实际医疗环境中正迅速获得商业性认可。

此外，降低的资本门槛和经济高效的扩充性正在推动成长，使高通量基因组数据的获取更加普及。这个可扩展平台使机构能够进行大规模人群研究和复杂的基因组组装，而无需承担与传统系统相关的高昂基础设施成本。这种高效性推动了硬体的普及。 2025年3月，《金融时报》报道称，由于利用率的提高，高容量Promecion产品线的收入成长了55.8%。这种运作上的扩充性建立在坚实的科学基础上。 IP Group在2025年报告称，前一年已发表了约3000篇使用该技术的同行评审论文，证实了其广泛的适用性。

市场挑战

全球奈米孔定序市场受到复杂数据分析的极大限制，而分析阻碍因素数据分析对于降低原始数据高错误率至关重要。奈米孔平台会产生复杂的电讯号，需要大规模的计算处理和专门的生物资讯工作流程来确保准确性。这些技术要求给用户带来了沉重的基础设施负担，实际上将缺乏资金或处理能力来应对如此繁重工作量的小规模研究机构和分散式诊断中心排除在外。

这种计算瓶颈对资源匮乏环境下的潜在使用者构成了重大进入障碍。管理复杂的生物数据是整个产业公认的难题。根据皮斯托亚联盟 (Pistoia Alliance) 2024 年的一项调查，54% 的生命科学专业人士认为非结构化资料是有效利用实验结果的主要障碍。这项统计数据凸显了实验室在处理原始和非标准化资料流（例如来自奈米孔设备的资料）时面临的操作难题。因此，缺乏先进资讯科学支援的机构不愿采用这些平台，从而延缓了该技术在常规临床和监测应用中的整合，而这些应用对简单性和速度要求极高。

市场趋势

人工智慧 (AI) 的整合应用于即时数据分析，正从根本上重塑全球奈米孔定序市场，其关键瓶颈在于数据复杂性。先进的机器学习演算法被整合到定序工作流程中，加速碱基鑑定和突变检测，有效抑制了以往阻碍该技术发展的高原始数据错误率。这种协同效应使得基因组讯号的即时边缘解读成为可能，从而减少了对大规模集中式运算基础设施的需求。英伟达在运算能力方面的投资也反映了这项变革的规模。 Sahm Capital 在 2025 年 1 月指出，分析师预测，到 2026 年，医疗保健产业将为英伟达带来 10 亿美元的年度经常性收入，这主要得益于对人工智慧驱动的基因组分析和药物发现平台的需求。

同时，市场正日益融合多元体学和蛋白​​质组学研究，从DNA分析扩展到全面的生物学分析。这一趋势推动奈米孔感测技术直接分析RNA分子和蛋白质结构，吸引了製药业在药物研发和品管方面的浓厚兴趣。该平台在商业研究中的日益普及也印证了其向工业应用的转变。根据牛津奈米孔技术公司2025年9月发布的数据，生物製药客户的营收年增18.5%，显示企业在受监管的治疗药物研发中越来越依赖多组体学奈米孔数据。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球奈米孔定序市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（消耗品、设备）
  • 依碱基序列（DNA、RNA）
  • 按类型（直流定序、合成DNA和侧向隧道电流定序、光学读取技术定序、核酸外切定序）
  • 奈米孔类型（固体、生物、混合）
  • 依应用领域（人类遗传学、临床研究、植物研究、微生物学、动物研究）
  • 依最终用户（生技公司、临床检查室、学术和研究机构）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美奈米孔定序市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲奈米孔定序市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区奈米孔定序市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲奈米孔定序市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲奈米孔定序市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球奈米孔定序市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Oxford Nanopore Technologies plc
• Illumina, Inc
• Agilent Technologies, Inc
• Roche Sequencing Solutions, Inc.
• 10X Genomics Inc
• Nabsys, Inc
• Laboratory Corporation of America Holdings
• Quantapore Inc
• INanoBio Inc
• Electronic BioSciences, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Nanopore Sequencing Market is projected to expand from USD 431.74 Million in 2025 to USD 790.66 Million by 2031, registering a CAGR of 10.61%. This technology determines nucleotide sequences by monitoring fluctuations in electrical current as nucleic acids pass through a solid-state or protein nanopore. The market's growth is largely fueled by the increasing need for long-read sequencing to decipher complex structural variants and the rising demand for portable, real-time pathogen monitoring in decentralized environments. Underscoring the importance of these diagnostic infrastructures, the World Health Organization reported in 2024 that the International Pathogen Surveillance Network provided nearly two million US dollars in grants to projects aimed at boosting global genomic analysis capabilities.

Despite these drivers, a major obstacle hindering broader market adoption is the complexity of data analysis required to correct raw read error rates, which remain higher than those of conventional short-read systems. This technical limitation demands significant computational power for accurate interpretation, establishing a high barrier to entry for smaller laboratories that lack sophisticated bioinformatics infrastructure. Consequently, the resource-intensive nature of data processing continues to challenge the technology's expansion into facilities with limited technical resources.

Market Driver

The expansion of applications within clinical diagnostics and precision medicine acts as a primary growth engine for the Global Nanopore Sequencing Market. As the technology evolves, it is transitioning from research settings to regulated healthcare environments, where it is used for rapid pathogen identification and human genetic profiling. This shift is highlighted by the increased deployment of nanopore-based tests in hospitals, offering faster results compared to traditional methods. According to FirstWord HealthTech, in its September 2025 report on Oxford Nanopore's interim results, revenue in the Clinical segment rose by 52.9% year-over-year, demonstrating the swift commercial acceptance of these diagnostic tools in practical medical scenarios.

Furthermore, reduced capital barriers and cost-effective scalability are driving growth by democratizing access to high-throughput genomic data. Scalable platforms allow institutions to conduct extensive population studies and complex genome assemblies without the high infrastructure costs associated with legacy systems. This efficiency has spurred hardware adoption; the Financial Times noted in March 2025 that revenue from the high-capacity PromethION product range increased by 55.8% as utilization rates climbed. This operational scalability is backed by a strong scientific foundation, with IP Group reporting in 2025 that approximately 3,000 peer-reviewed papers utilizing this technology were published the previous year, confirming its wide-ranging applicability.

Market Challenge

The Global Nanopore Sequencing Market faces a significant restraint due to the intricate data analysis required to mitigate high raw read error rates. Nanopore platforms produce complex electrical signals that necessitate extensive computational processing and specialized bioinformatics workflows to ensure accuracy. This technical requirement places a heavy infrastructure burden on users, effectively excluding smaller research facilities and decentralized diagnostic centers that lack the financial means or processing capabilities to manage such demanding workloads.

This computational bottleneck creates a critical barrier to entry for potential users in resource-limited settings. The challenge of managing complex biological data is a recognized issue across the industry; according to the Pistoia Alliance in 2024, 54% of life science experts identified unstructured data as a major obstacle to effectively using experimental outputs. This statistic emphasizes the operational difficulties laboratories face when dealing with raw, non-standardized data streams like those from nanopore devices. Consequently, organizations without advanced informatics support are deterred from adopting these platforms, slowing the technology's integration into routine clinical and surveillance applications where simplicity and speed are essential.

Market Trends

The integration of Artificial Intelligence for real-time data analytics is fundamentally reshaping the Global Nanopore Sequencing Market by resolving the critical bottleneck of data complexity. Advanced machine learning algorithms are being embedded into sequencing workflows to accelerate basecalling and variant detection, effectively counteracting the high raw read error rates that historically challenged the technology. This synergy enables immediate, edge-based interpretation of genomic signals, reducing the need for massive centralized computing infrastructure. The scale of this shift is reflected in the investment in computing power; Sahm Capital noted in January 2025 that analysts expect the healthcare sector to contribute one billion US dollars in annual recurring revenue to Nvidia by 2026, driven largely by the demand for AI-driven genomic and drug discovery platforms.

Simultaneously, the market is witnessing a convergence with multi-omics and proteomics research, expanding beyond DNA analysis to comprehensive biological profiling. This trend involves broadening nanopore sensing capabilities to directly analyze RNA molecules and protein structures, attracting significant interest from the pharmaceutical sector for drug development and quality control. This move toward industrial application is evidenced by the rising adoption of these platforms in commercial research; according to Oxford Nanopore Technologies in September 2025, revenue from the BioPharma customer segment grew by 18.5% year-over-year, highlighting the increasing reliance on multi-omic nanopore data for regulated therapeutic development.

Key Market Players

• Oxford Nanopore Technologies plc
• Illumina, Inc
• Agilent Technologies, Inc
• Roche Sequencing Solutions, Inc.
• 10X Genomics Inc
• Nabsys, Inc
• Laboratory Corporation of America Holdings
• Quantapore Inc
• INanoBio Inc
• Electronic BioSciences, Inc.

Report Scope

In this report, the Global Nanopore Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nanopore Sequencing Market, By Product

• Consumables
• Instruments

Nanopore Sequencing Market, By Nucleotide Sequenced

• DNA
• RNA

Nanopore Sequencing Market, By Type

• Direct Current Sequencing
• Synthetic DNA and Horizontal Tunnelling Current Sequencing
• Optical Reading Techniques Sequencing
• Exonuclease Sequencing

Nanopore Sequencing Market, By Type of Nanopore

• Solid State
• Biological
• Hybrid

Nanopore Sequencing Market, By Application

• Human Genetics
• Clinical Research
• Plant Research
• Microbiology
• Animal Research

Nanopore Sequencing Market, By End User

• Biotechnology Companies
• Clinical Laboratories
• Academic & Research Institutes

Nanopore Sequencing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nanopore Sequencing Market.

Available Customizations:

Global Nanopore Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nanopore Sequencing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables, Instruments)
  • 5.2.2. By Nucleotide Sequenced (DNA, RNA)
  • 5.2.3. By Type (Direct Current Sequencing, Synthetic DNA and Horizontal Tunnelling Current Sequencing, Optical Reading Techniques Sequencing, Exonuclease Sequencing)
  • 5.2.4. By Type of Nanopore (Solid State, Biological, Hybrid)
  • 5.2.5. By Application (Human Genetics, Clinical Research, Plant Research, Microbiology, Animal Research)
  • 5.2.6. By End User (Biotechnology Companies, Clinical Laboratories, Academic & Research Institutes)
  • 5.2.7. By Region
  • 5.2.8. By Company (2025)
• 5.3. Market Map

6. North America Nanopore Sequencing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Nucleotide Sequenced
  • 6.2.3. By Type
  • 6.2.4. By Type of Nanopore
  • 6.2.5. By Application
  • 6.2.6. By End User
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nanopore Sequencing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Nucleotide Sequenced
      • 6.3.1.2.3. By Type
      • 6.3.1.2.4. By Type of Nanopore
      • 6.3.1.2.5. By Application
      • 6.3.1.2.6. By End User
  • 6.3.2. Canada Nanopore Sequencing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Nucleotide Sequenced
      • 6.3.2.2.3. By Type
      • 6.3.2.2.4. By Type of Nanopore
      • 6.3.2.2.5. By Application
      • 6.3.2.2.6. By End User
  • 6.3.3. Mexico Nanopore Sequencing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Nucleotide Sequenced
      • 6.3.3.2.3. By Type
      • 6.3.3.2.4. By Type of Nanopore
      • 6.3.3.2.5. By Application
      • 6.3.3.2.6. By End User

7. Europe Nanopore Sequencing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Nucleotide Sequenced
  • 7.2.3. By Type
  • 7.2.4. By Type of Nanopore
  • 7.2.5. By Application
  • 7.2.6. By End User
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nanopore Sequencing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Nucleotide Sequenced
      • 7.3.1.2.3. By Type
      • 7.3.1.2.4. By Type of Nanopore
      • 7.3.1.2.5. By Application
      • 7.3.1.2.6. By End User
  • 7.3.2. France Nanopore Sequencing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Nucleotide Sequenced
      • 7.3.2.2.3. By Type
      • 7.3.2.2.4. By Type of Nanopore
      • 7.3.2.2.5. By Application
      • 7.3.2.2.6. By End User
  • 7.3.3. United Kingdom Nanopore Sequencing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Nucleotide Sequenced
      • 7.3.3.2.3. By Type
      • 7.3.3.2.4. By Type of Nanopore
      • 7.3.3.2.5. By Application
      • 7.3.3.2.6. By End User
  • 7.3.4. Italy Nanopore Sequencing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Nucleotide Sequenced
      • 7.3.4.2.3. By Type
      • 7.3.4.2.4. By Type of Nanopore
      • 7.3.4.2.5. By Application
      • 7.3.4.2.6. By End User
  • 7.3.5. Spain Nanopore Sequencing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Nucleotide Sequenced
      • 7.3.5.2.3. By Type
      • 7.3.5.2.4. By Type of Nanopore
      • 7.3.5.2.5. By Application
      • 7.3.5.2.6. By End User

8. Asia Pacific Nanopore Sequencing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Nucleotide Sequenced
  • 8.2.3. By Type
  • 8.2.4. By Type of Nanopore
  • 8.2.5. By Application
  • 8.2.6. By End User
  • 8.2.7. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Nanopore Sequencing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Nucleotide Sequenced
      • 8.3.1.2.3. By Type
      • 8.3.1.2.4. By Type of Nanopore
      • 8.3.1.2.5. By Application
      • 8.3.1.2.6. By End User
  • 8.3.2. India Nanopore Sequencing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Nucleotide Sequenced
      • 8.3.2.2.3. By Type
      • 8.3.2.2.4. By Type of Nanopore
      • 8.3.2.2.5. By Application
      • 8.3.2.2.6. By End User
  • 8.3.3. Japan Nanopore Sequencing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Nucleotide Sequenced
      • 8.3.3.2.3. By Type
      • 8.3.3.2.4. By Type of Nanopore
      • 8.3.3.2.5. By Application
      • 8.3.3.2.6. By End User
  • 8.3.4. South Korea Nanopore Sequencing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Nucleotide Sequenced
      • 8.3.4.2.3. By Type
      • 8.3.4.2.4. By Type of Nanopore
      • 8.3.4.2.5. By Application
      • 8.3.4.2.6. By End User
  • 8.3.5. Australia Nanopore Sequencing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Nucleotide Sequenced
      • 8.3.5.2.3. By Type
      • 8.3.5.2.4. By Type of Nanopore
      • 8.3.5.2.5. By Application
      • 8.3.5.2.6. By End User

9. Middle East & Africa Nanopore Sequencing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Nucleotide Sequenced
  • 9.2.3. By Type
  • 9.2.4. By Type of Nanopore
  • 9.2.5. By Application
  • 9.2.6. By End User
  • 9.2.7. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Nanopore Sequencing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Nucleotide Sequenced
      • 9.3.1.2.3. By Type
      • 9.3.1.2.4. By Type of Nanopore
      • 9.3.1.2.5. By Application
      • 9.3.1.2.6. By End User
  • 9.3.2. UAE Nanopore Sequencing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Nucleotide Sequenced
      • 9.3.2.2.3. By Type
      • 9.3.2.2.4. By Type of Nanopore
      • 9.3.2.2.5. By Application
      • 9.3.2.2.6. By End User
  • 9.3.3. South Africa Nanopore Sequencing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Nucleotide Sequenced
      • 9.3.3.2.3. By Type
      • 9.3.3.2.4. By Type of Nanopore
      • 9.3.3.2.5. By Application
      • 9.3.3.2.6. By End User

10. South America Nanopore Sequencing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Nucleotide Sequenced
  • 10.2.3. By Type
  • 10.2.4. By Type of Nanopore
  • 10.2.5. By Application
  • 10.2.6. By End User
  • 10.2.7. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nanopore Sequencing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Nucleotide Sequenced
      • 10.3.1.2.3. By Type
      • 10.3.1.2.4. By Type of Nanopore
      • 10.3.1.2.5. By Application
      • 10.3.1.2.6. By End User
  • 10.3.2. Colombia Nanopore Sequencing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Nucleotide Sequenced
      • 10.3.2.2.3. By Type
      • 10.3.2.2.4. By Type of Nanopore
      • 10.3.2.2.5. By Application
      • 10.3.2.2.6. By End User
  • 10.3.3. Argentina Nanopore Sequencing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Nucleotide Sequenced
      • 10.3.3.2.3. By Type
      • 10.3.3.2.4. By Type of Nanopore
      • 10.3.3.2.5. By Application
      • 10.3.3.2.6. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Nanopore Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Oxford Nanopore Technologies plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Illumina, Inc
• 15.3. Agilent Technologies, Inc
• 15.4. Roche Sequencing Solutions, Inc.
• 15.5. 10X Genomics Inc
• 15.6. Nabsys, Inc
• 15.7. Laboratory Corporation of America Holdings
• 15.8. Quantapore Inc
• 15.9. INanoBio Inc
• 15.10. Electronic BioSciences, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer